D'après la communication de : Cosimo De Bari, Francesco Dell'Accio, Johan Neys, Frank P Luyten Leuven, Belgium. [Abstract 289] Human synovial membrane-derived mesenchymal stem cells for skeletal muscle repair Rapporté par Philippe Brissaud

D'après la communication de : Nisha J Manek, Deborah Hart, Tim D Spector, Alex J MacGregor London, United Kingdom. [Abstract 287] Association of obesity and severity of knee ostéoarthritis is not mediated by shared genetic influences Rapporté par Philippe Brissaud

D'après la communication de : Michael A Maldonado, Takashi Miwa, Hong Yuan Luo, Victoria P Werth, Michael P Madaio, Robert A Eisenberg, Wen-Chao Song Philadelphia, PA [Abstract 661] THE ROLE OF MEMBRANE COMPLEMENT REGULATOR DECAY ACCELERATING FACTOR (DAF, CD55) IN THE MRL-LPR MURINE MODEL OF SYSTEMIC AUTOIMMUNITY. Rapporté par Philippe Brissaud, Paris

D'après la communication de : Matthew C Pickering, Joanna Warren, Anne E Bygrave, Jill Moss, Robert E Sim, H Terence Cook, Mark J Walport, Marina Botto London, United Kingdom [Abstract 662] UNCONTROLLED ALTERNATIVE PATHWAY ACTIVATION AND TISSUE INJURY IN FACTOR H-DEFICIENT MICE. Rapporté par Philippe Brissaud, Paris

D'après la communication de : Christopher Thunberg, Nancy Zurowski, Jeannine Navratil, Stefania Ursu, Marina Botto, Mark Walport, Joseph Ahearn Pittsburgh, PA and London, United Kingdom [Abstract 659] DEFICIENCY OF C1q LEADS TO GENERATION OF APOPTOTIC KERATINOCYTES BEARING C3- BUT NOT C4-DERIVED LIGANDS IN VIVO: IMPLICATIONS FOR THE PATHOGENESIS OF SLE. Rapporté par Philippe Brissaud, Paris

D'après la communication de : P Mease, A Kivitz, F Burch, E Siegel, S Cohen, D Burge Seattle, WA; Duncansville, PA; San Antonio and Dallas TX; Wheaton, MD. (Abtract 226) Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®) : results of a phase 3 multicenter clinical trial Rapporté par Philippe Brissaud, Paris

D'après la communication de : Jennifer D Gorman, Kenneth E Sack, John C Davis San Francisco, CA. (Abstract 224) A randomized, double-blind, placebo-controlled trial of etanercept (Enbrel®) in the treatment of ankylosing spondylitis Rapporté par Philippe Brissaud, Paris

D'après la communication de : Maxime Breban, Eric Vignon, Pascal Claudepierre, Alain Saraux, Daniel Wendling, Eric Lespessailles, Liana Euler Ziegler, Jean Sibilia, Aleth Perdriger, Christian Alexandre, Maxime Dougados Paris, Lyon, Brest, Besancon, Orleans, Nice, Strasbourg, Rennes and Saint-Etienne, France. (Abstract 222) Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of 6 months follow-up open-label study Rapporté par Philippe Brissaud, Paris

D'après la communication de : Huibert J Dinant, Arno WR van Kuijk, Amber Y Goedkoop, Maarten C Kraan, Menno A de Rie, Ben AC Dijkmans, Akshay Vaishnaw, Paul P Tak Amsterdam, Netherlands; Cambridge, MA [Abstract 233] ALEFACEPT (LFA3-IgG1 FUSION PROTEIN, LFA3TIP) REDUCES SYNOVIAL INFAMMATORY INFILTRATE AND IMPROVES OUTCOME IN PSORIATIC ARTHRITIS. Rapporté par Michel Bodin, Paris

D'après la communication de : C E Antoni, C Dechant, H Haentzschel, R Alten, H Soerensen, A Schwebig, J R Kalden, B Manger Erlangen, Leipzig, Berlin and Munich, Germany [Abstract 187] SAFETY AND EFFICACY OF INFLIXIMAB IN 263 PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) DESPITE METHOTREXATE THERAPY: A GERMAN OPEN LABEL TRIAL. Rapporté par Michel Bodin, Paris